Abstract 114P
Background
Pathogenic or likely pathogenic germline variants (PGVs) in cancer predisposition genes may play a role in lung cancer (LC) susceptibility. However, determining an eligible population for genetic testing remains uncertain. This study aimed to assess the prevalence of PGVs in a selected cohort of individuals with lung adenocarcinoma.
Methods
A cross-sectional cohort study was conducted to assess PGVs rate in lung adenocarcinoma patients with a family history of LC, young-onset presentation, history of never/light smoking, or actionable genomic alterations (AGAs). Sequencing was performed using Sophia Hereditary Cancer Solution panel F, including 144 cancer predisposition genes. Variants classified as pathogenic or likely pathogenic were included for further analysis.
Results
We incluided 201 patients, of which 43 (21.4%) exhibited PGVs, identifying that 64.5% occurred in DNA damage repair genes, being 86.1% clinically actionable. The most frequent PGVs were found in ATM (9.3%), TP53 (6.9%), BRCA2 (6.9%), and CHEK2 (6.9%) genes. PGVs were associated with male sex (adjusted odds ratio [aOR] 2.54, 95% CI 1.17–5.53, p=0.019), very young-onset presentation (aOR 5.79, 95% CI 1.35–24.74, p=0.018), and first-degree relatives with LC (aOR 3.78, 95% CI 1.11–12.83, p=0.033), along with a trend toward association with AGAs (aOR 6.42, 95% CI 0.79–52.18, p=0.082).
Conclusions
This study identified a high PGVs prevalence based on our selection criteria, thus representing an effective strategy to select candidates for germline genomic testing, potential screening strategies in close relatives, and personalized therapeutic modalities. Our results warrant further exploration in other populations to confirm them.
Clinical trial identification
NCT06181812.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by CONAHCyT (A3-S-47960) and Becas Impulso a La Investigación En Salud “Carlos Slim” 2023 (N20230149).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Efficacy of immunotherapy in gastro-intestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype
Presenter: Emily Alouani
Session: Poster session 08
144P - Analysis of a novel predictive marker of immune checkpoint response in head and neck cancer, calculated from histopathological slides through inferred transcriptomics
Presenter: Johnathan Arnon
Session: Poster session 08
145P - Predicting the efficacy of immunotherapy in non-small cell lung cancer using machine learning based on simple clinical characteristics and biochemical indexes
Presenter: Lei Cheng
Session: Poster session 08
146P - Biomarkers and intrinsic/acquired resistance mechanisms for atezolizumab plus chemoradiotherapy in MSS locally advanced rectal cancer: An exploratory analysis of a single center, phase II study
Presenter: Wentao Tang
Session: Poster session 08
147P - Comparison of immune-checkpoint inhibitor therapy predictive marker tests microsatellite instability (MSI) and mismatch-repair deficiency (dMMR)
Presenter: Maja Nádorvári
Session: Poster session 08
148P - Clinical significance of CD4+ T cell subsets in peripheral blood for anti-PD-1/PD-L1 therapy
Presenter: Yoshimichi Haruna
Session: Poster session 08
149P - Evaluation of HLA genotype as predictive biomarker for immunological and clinical responses upon vaccination with PolyPEPI1018 cancer vaccine against colorectal cancer
Presenter: Joleen Hubbard
Session: Poster session 08
150P - Phase I/IIa trial of CD200R1 inhibitor 23ME-00610: Exploratory analyses of tissue-based and genetic biomarkers
Presenter: Albiruni Ryan Abdul Razak
Session: Poster session 08
151P - Enhanced pharmacodynamic effects upon combination of cibisatamab and FAP-4-1BBL in 3L+ mMSS CRC patients
Presenter: Ignacio Melero
Session: Poster session 08
152P - Exploratory biomarker analysis of phase III ASTRUM-004 study: Serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer
Presenter: Caicun Zhou
Session: Poster session 08